新型冠状病毒肺炎与新发病毒性传染病：干扰素 λ的作用。
COVID-19 and emerging viral infections: The case for interferon lambda.
机构信息
Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK.
出版信息
J Exp Med. 2020 May 4;217(5). doi: 10.1084/jem.20200653.
With the first reports on coronavirus disease 2019 (COVID-19), which is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the scientific community working in the field of type III IFNs (IFN-λ) realized that this class of IFNs could play an important role in this and other emerging viral infections. In this Viewpoint, we present our opinion on the benefits and potential limitations of using IFN-λ to prevent, limit, and treat these dangerous viral infections.
随着新型严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）引起的 2019 年冠状病毒病（COVID-19）的首批报告的出现，从事 III 型干扰素（IFN-λ）领域研究的科学界意识到，这类干扰素可能在这类和其他新发病毒感染中发挥重要作用。在本观点中，我们就使用 IFN-λ预防、限制和治疗这些危险病毒感染的益处和潜在局限性提出我们的看法。
Zotero 插件